Home/ Stocks/ CTXR

Citius Pharmaceuticals Inc. Common

CTXR XNAS

$0.68 +0.06 (+9.74%) ▲ 15-min delayed

Open

$0.66

High

$0.70

Low

$0.64

Volume

442.5K

Market Cap

$17.62M

About Citius Pharmaceuticals Inc. Common

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 23 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$1.67M	$-28,109,746	$-0.95
Q1 2026	$3.94M	$-9,393,889	$-0.38
FY 2025	$0	$-39,740,269	$-3.38
Q3 2025	$0	$-9,203,872	$-0.80

Related Market News

No specific coverage for CTXR yet. Check out our latest market news or earnings calendar.

Get CTXR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Citius Pharmaceuticals Inc. Common.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.